Events
APIS goes ECCMID 2024!
Don’t miss APIS at ECCMID 27th April, 2024
Come and meet our team of expertise at booth F32
It’s a perfect chance to discuss:
· Contract assay development opportunities
· Clinical Compliance Services
· Clickmers
· Infectious disease and microbiology capabilities
Interested? Contact us to arrange a meeting: Contact — APIS Assay Technologies Ltd
APIS goes to BioIT-World Conference & Expo
Heading to BioIT-World Conference in Boston 15-17 April?
So is our Head of Bioinformatics, Aleksandar Mihajlovic
It’s a perfect chance to discuss:
· Opportunities in AI & ML for biomarker and drug discovery
· Algorithm and bioinformatics pipeline development and evidence extrapolation from data
· Bioinformatics cloud platforms development
Interested? Schedule a call with us via our booking link: https://bit.ly/ApisBioinformatics
Streamlining Biomarker Discovery: From Theory to Application
🌟 Webinar Alert! 🌟
Streamlining Biomarker Discovery: From Theory to Application
Join us for an educational webinar session as we delve into the fascinating world of biomarker discovery and its crucial role in Breast Cancer Subtyping. Our presenters Svetozar Nesić and Marko Tumbas from APIS Assay Technologies, will guide you through the complexities of this cutting-edge field.
🔍 Webinar Highlights:
Biomarker selection
Designing a biomarker signature
Develop a predictive algorithm capable of addressing the high dimensionality of biological datasets
Determine the minimal marker subset capable of achieving the desired predictive power
Translate findings obtained using data to train ML models and test obtained signature robustness
📅 Date: 11th April 2024 ⏰ Time: 14:00 (BST)
Don’t miss this opportunity to gain practical knowledge and network with fellow enthusiasts. Register now 🚀 https://attendee.gotowebinar.com/register/2901291665925058903?source=APIS+Website
Want to learn more? Book a meeting with us to discuss 👉 https://bit.ly/ApisBioinformatics
ESR1 Mutations as Essential Markers for Understanding Endocrine Therapy Resistance
Oestrogen receptor 1 (ER/ESR1) mutations have arisen as crucial biomarkers for endocrine therapy resistance in ER positive metastatic breast cancer. Detecting these mutations is key for understanding acquired resistance during treatment.
APIS will be joined by SensID GmbH to deliver this FREE educational webinar on ESR1 mutations and the importance of their accurate and sensitive detection.
Gain insights into:
- ESR1 mutations significance in breast cancer and their role in endocrine therapy resistance
- APIS ESR1 Mutations Kit, an accessible method to detect ESR1 mutations
- SensID ESR1 reference set to ensure accurate detection of mutations in cell-free DNA (cfDNA)
Have your questions answered by experts in gene mutation assay development and validation!
Register here: https://attendee.gotowebinar.com/register/8248345354064775003?source=APIS+Website
Clickmers® webinar
Join us for our educational webinar on ‘Clickmers® as a Powerful Tool in a Rapidly Changing Pathogen Landscape’.
Clickmers are versatile DNA-based detection molecules that can be used in various types of assays ranging from diagnostics to therapeutics.
Gain insights into:
The fundamentals of Clickmers, their role, and significance in therapeutics and diagnostics
How Clickmers unique properties enable faster responses to emerging pathogens
How Clickmers can differentiate between tick-borne encephalitis (TBEV) NS1 and other highly similar flavivirus NS1 protein
We hope you can join us on: Thursday 15th February, 14:00-15:00 (GMT)
Register to secure your spot: https://attendee.gotowebinar.com/register/6764377390145455196?source=APIS+LinkedIn
BioX Webinar Ep.3
Join us for the third episode of our educational webinars, this time on "Navigating the Future of Drug Discovery: Public Data & AI in Target Discovery"
During this session, Aleksandar Mihajlovic and Aleksandra Gulbicka (APIS Assay Technologies Ltd.) will guide you through the realm of drug discovery, exploring the synergistic integration of public data and AI.
Don’t miss gaining valuable insights into:
· Setting the Stage for Innovation: Discover how the convergence of public data and AI is reshaping the landscape of pharmaceutical research
· Modifying Questions for Biomarkers: Explore novel strategies for adapting biomarker-related questions in drug discovery research
· Clickmers: Uncover the fundamentals of Clickmers, their role, and significance in modern drug discovery
We hope you can join us on: Thu 14th December, 14:00-15:00 (GMT)
Register to secure your spot 👉 https://bit.ly/3RboQfS
Precision Oncology Europe
Dont miss APIS presenting at Precision Oncology Europe - ‘Advantages of Using Clickmer Technology for the Detection of Biomarkers’
Dr. Nora Karnowski’s presentation will outline the advantages of Clickmer technology and how they can support biomarker development:
Clickmers are modified DNA aptamers that bind to their biomarker targets with nanomolar affinity. They can be developed within weeks, have high specificity and can be quantified using enzymatic, fluorescent, or qPCR readout for improved sensitivity.
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.
Use this link to contact us and schedule a meeting.
AMP 2023
Join the APIS team at AMP 2023
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutics into clinical utility.
Find out about our expertise and capabilities in IVD development of molecular & immune-assays for product realisation as diagnostic tests. APIS expertise in bioinformatics is offered as an agile service, to develop bespoke, end-to-end multi-OMICs solutions and platform development.
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.
Use this link to contact us and schedule a meeting
Decoding the Future: How Cloud Computing is Reshaping Bioinformatics
Join us for the second episode of our educational webinars on "Decoding the Future: How Cloud Computing is Reshaping Bioinformatics".
During this session, presenters Nikola Nonkovic (APIS Assay Technologies) and Victor Weigman (BioSkryb) will guide you through the transformative journey of bioinformatics from its inception in traditional data centers to the expansive possibilities within the cloud.
Webinar highlights:
The Evolution of Bioinformatics: Traverse the journey from data centers to the limitless potential of the cloud.
Cloud Technologies & Bioinformatics: Understand the profound impact of cloud solutions in the realm of bioinformatics, specifically as it applies to single-cell genomic and transcriptomic analysis.
To Build or Not to Build: Delve into the decision-making process behind creating custom bioinformatics applications versus licensed solutions.
We hope you can join us on: Thu 26th October, 15:00-16:00 (GMT)
Register to secure your spot: https://bit.ly/3tkNSRw
APIS are presenting at ACRO Biosystems Symposium
Don’t miss APIS presenting at ACRO Biosystems Symposium - ‘The potential of Clickmers to accelerate the development of safer drugs’
Dr. Nora Karnowski’s presentation will outline how the Clickmer technology can support drug development
Fast discovery, characterisation and assay development to aid e.g. patient stratification
Innovative selection methods to achieve special features such as targeting of undruggables like GPCRs or conditional activation
Register now 👉: https://bit.ly/3FmjusL
BioTechX Europe Conference
Don’t miss the APIS team at BioTechX Europe!
APIS is leveraging systems biology and interrogating multi-OMICs biodata for the validation and translation of biomarker into clinical utility.
Utilising the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data APIS directly addresses the historical failures of translating biomarkers into clinical utility.
Operating under an ISO 13485 QMS, APIS seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.
Use this link to contact us and schedule a meeting.
Nextflow Bioinformatics Pipelines and Workflow Management: A Comprehensive Webinar
Join Srdjan Kasapovic and guest speaker Dr. Harshil Patel (Seqera Labs) for an informative webinar on "Nextflow Bioinformatics Pipelines and Workflow Management".
In this session, we will provide valuable insights into:
Nextflow bioinformatics pipelines
Pipeline design best practices
The difference between open source and commercial pipelines
Nextflow Tower for efficient workflow management
We hope you can join us on:
Tue 19th September, 16:00 PM - 17:00 PM (CEST)
Register here to secure your spot and have your questions answered by our expert presenters!
35th European Congress of Pathology
Join the APIS team at the 35th European Congress of Pathology in Dublin, Ireland.
APIS is leveraging systems biology and interrogating multi-OMICs biodata for the validation and translation of biomarker into clinical utility.
We proudly present:
The APIS Breast Cancer Subtyping Kit, a highly reproducible, RT-qPCR based product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The new APIS ESR1 Mutations Kit, an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.
Use this link to contact us and schedule a meeting.
World Clinical Biomarker & CDx 2023
The APIS team will be exhibiting and presenting at the 13th World Clinical Biomarker & CDx 2023 in Boston.
Be sure not to miss Program Lead, Joanna Gorniak, PhD, presenting on Day 2, Friday 8th September at 4 PM with her talk titled ‘HER2 Stratification with a Novel Diagnostic Test’.
APIS is leveraging the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data to directly address the historical failures of translating biomarkers into clinical utility.
Operating under an ISO 13485 QMS, APIS seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.
Use this link to contact us and schedule a meeting.
AACC Annual Scientific Meeting & Clinical Lab Expo 2023
The APIS team will be exhibiting at AACC Annual Scientific Meeting & Clinical Lab Expo 2023.
Be sure not to miss our team of experts at Booth 2482.
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutics into clinical utility.
Find out about our expertise and capabilities in IVD development of molecular & immune-assays for product realisation as diagnostic tests. APIS expertise in bioinformatics is offered as an agile service, to develop bespoke, end-to-end multi-OMICs solutions and platform development.
The APIS Breast Cancer Subtyping Kit (RUO) is a highly reproducible, RT-qPCR based product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The new APIS ESR1 Mutations Kit is a research use only, advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
Use this link to contact us and schedule a meeting.
Liverpool Pathology 2023
Join the APIS Team at Liverpool Pathology 2023 for the 14th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society.
27-29th June 2023
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.
APIS has deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as IVD tests.
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The new APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
Interested in learning more? Use this link to contact us and schedule a meeting.
Antibody Engineering & Therapeutics Europe
The APIS team will be exhibiting and speaking at the Antibody Engineering & Therapeutics Europe conference at the Postillion Hotel, Amsterdam.
Come and meet us at stand 21.
APIS’ deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as diagnostic tests.
Innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.
The APIS SARS-CoV-2 IgG ELONA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum and utilises Clickmers. The results of this assay will aid in clinical decision making, vaccine development and booster dosing, and clinical research studies.
Interested in learning more? Use this link to contact us and schedule a meeting.
Clickmers Webinar
Join Dr. Maren Hamann and Dr. Nora Karnowski for a must-attend virtual webinar that will introduce the revolutionary Clickmer Systems.
Synthetic affinity reagents known as Clickmers are chemically modified ssDNA oligonucleotides that, based on their sequence and modifications, form three-dimensional structures that adaptively bind to their target molecules with high affinity and specificity.
Clickmers can be used, for example, to detect viral infections, determine vaccination status or detect rejection reactions after organ transplants.
We hope you can join us on:
Tue 9th May, 14:00 PM - 15:00 PM (GMT)
To register follow the link: https://bit.ly/3AhWvwh
13th Clinical Biomarkers & CDx Europe 2023
The APIS Team will be exhibiting and presenting at the 13th Clinical Biomarkers & CDx Europe 2023 in London.
Be sure not to miss our Chief Operating Officer, Ian Kavanagh, presenting on Day 1 at 9:50 AM in the plenary session with his talk titled ‘HER2 Stratification with a Novel Diagnostic Test’.
Discovering the potential of the APIS Breast Cancer Subtyping Kit for faster HER2 result turnaround without the need for reflex testing to ISH
Learning how to significantly reduce time for results interpretation with automatic results via validated software
The detection ability of lowly expressed ERBB2 levels aligns the IVD test as a CDx to HER2 targeted therapies, such as Trastuzumab deruxtecan
Interested in learning more? Use this link to contact us and schedule a meeting.
ECCMID 2023
The APIS Team will be exhibiting at ECCMID 2023 in Copenhagen, Denmark.
APIS Assay Technologies core expertise and capabilities are contract development of molecular & immunoassay assays and their ultimate product realisation as IVD approved assays, and the related clinical compliance services (particularly for CE-IVDR).
Operating under ISO 13485 and supported by the required clinical & compliance teams, we have expertise in developing PCR (RT-qPCR, qPCR, dPCR), NGS and immunoassay (e.g. ELISA & ELONA) IVD tests. Our onsite microbiology facilities provide our clients the capabilities to develop multiplex infectious disease panels in-house.
Our new APIS SARS-CoV-2 IgG ELISA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum. The assays’ results will aid in clinical decision making, vaccine development and booster dosing, disease prevention and research studies.
Interested in learning more? Use this link to contact us and schedule a meeting.
APIS Belgrade nf-core Hackathon
The APIS Belgrade team are hosting a ‘local hub’ for the nf-core Hackathon.
nf-core is a community that builds and maintains best-practices curated analysis pipelines (https://nf-co.re), spanning a wide range of bioinformatics domains that include genomics, metagenomics, transcriptomics, proteomics, and metabolomics.
The nf-core hackathon is a biannual event where the nf-core community gather online for 3 days of hacking all things nf-core. To support the hackathon further, APIS Belgrade with be hosting a ‘local hub’ for the event at Startit Centar, Beograd, where community members can gather and attend the online event together.
This will be held on the 27-29th March 2023.
If you’re close by and interested in joining the hackathon in-person to connect and work on Nextflow nf-core pipelines, visit https://bit.ly/3mnUjQb and select ‘APIS Assay Technologies Ltd, Belgrade, Serbia' in the registration form.
Registration closes 17th March.
Online Nextflow and nf-core community training is also available 13-16th March (http://bit.ly/3YzkOzS), although not required for the hackathon.
13th Annual World ADC London
The APIS Team will be exhibiting at the 13th Annual World ADC in London, UK. Come and meet us at Booth 23.
At the 13th World ADC we will be discussing 3 key solutions that will help advance the development of antibody-drug conjugates:
Innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.
APIS’ deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as IVD tests.
The new APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
Interested in learning more? Use this link to contact us and schedule a meeting.
Biomarkers 2023
The APIS team will be exhibiting and speaking at the Biomarkers 2023 in Manchester, UK on the 27 and 28th February 2023.
Be sure not to miss our Technical Development Lead, Joanna Gorniak PhD, presenting on Day 1 at 11:35 AM in Track 3 with the talk title ‘Development of a Novel Breast Cancer Subtyping and Proliferation Gene Expression Diagnostic Test’.
Interested in learning more? Use this link to contact us and schedule a meeting.
Next Generation Antibody Therapeutics: From Discovery to Patient
The APIS team will have a Poster and Short Talk at Next Generation Antibody Therapeutics: From Discovery to Patient in Banff, Canada, 19-23rd February 2023.
Be sure not to miss Nora Karnowski PhD, MBA, Head of Operations, Clickmer Systems GmbH, presenting a Short Talk on Day 3 between 08:00 to 11:00 AM in the track Discovery Platforms with the talk title ‘Targeting Highly Homologous Pathogens With Supremely Specific Clickmers’.
Interested in learning more? Use this link to contact us and schedule a meeting.
Festival of Genomics & Biodata
The APIS team will be exhibiting and speaking at the Festival of Genomics & Biodata in London, UK on the 25 and 26th January 2023.
Be sure not to miss our Head of Operations for Bioinformatics, Aleksandar Mihajlovic, presenting on Day 2 at 2:10 PM in the Live Lounge with his talk titled ‘Adapting Bulk Seq Methods in the Analysis of Single Cell Genomes’.
Interested in learning more? Use this link to contact us and schedule a meeting.
BioTechX 2022
The Apis team will be exhibiting and speaking at this year’s BioTechX Conference in Basel, Switzerland from the 8th - 10th November 2022.
Be sure not to miss our Head of Operations for Bioinformatics, Aleksandar Mihajlovic, presenting on Day 1 at 2:40 PM.
Interested in learning more? Use this link to contact us and schedule a meeting.
Biomarker Analysis Europe
The Apis team will be attending, exhibiting, and speaking at this year’s Oxford Global Biomarker Analysis Europe Conference in Berlin, Germany on the 1st and 2nd November 2022.
The conference will delve into current biomarker research, applications and development, as well as focusing on the tumour microenvironment and associated technologies.
Be sure not to miss out on Dr. Helen Fielder presenting the capabilities of our recently launched Apis Breast Cancer Subtyping Kit at 12PM on Day 2.
Interested in learning more? Use this link to contact us and schedule a meeting.
BioNow Oncology & Precision Medicine
The Apis Team will be attending in person as a Gold Exhibitor at the BioNow Oncology & Precision Medicine Conference 2022 at Alderley Park, Manchester, UK.
The conference will highlight the current status of precision medicine and oncology in the Nation, with an emphasis on early detection and diagnosis.
We will be showcasing our newly launched Apis Breast Cancer Subtyping Kit.
https://www.bionow.co.uk/event/BIONOW140/oncology-precision-medicine-conferences-2022
12th World Clinical Biomarkers & CDx Summit
The Apis Team will be exhibiting and speaking in person at the 12th World Clinical Biomarkers & CDx Summit in Boston, USA.
Be sure not to miss Ian Kavanagh (COO & Co-Founder) talking on the ‘Development of a Novel Breast Cancer Subtyping and Proliferation Gene Expression Diagnostic Test’ in the Defining Patient Populations Track – 28th September @ 15:20 – 15:50 (EST).
Abstract
This talk will encompass the development of our novel ‘Breast Cancer Subtyping and Proliferation Gene Expression Diagnostic Test’:
• A RT-qPCR nucleic acid-based IVD test for the detection and relative gene expression quantification of human mRNA target genes from pre-operative CNB or resected FFPE breast tumour tissue from patients with invasive breast cancer.
• Breast cancer subtyping performance of the IVD test is determined by concordance to that assigned by the current histopathology IHC reference methodology.
• In addition to its primary clinical utility as an MDx, the potential for detection of lowly expressed ERBB2 (HER2) levels aligns the IVD test as a CDx to HER2 targeted therapies e.g. Trastuzumab deruxtecan (Enhertu).
Interested in learning more? Use this link to contact us and schedule a meeting.
ON Helix 2022
The Apis Team will be attending in person the One Nucleus Helix 2022 in Cambridge, UK.
The ON Helix 2022 will discuss the main bio innovation trends, from the developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments.
To hear more about how Apis Assay are disrupting the diagnostic space, use this link to contact us and schedule a meeting.
BioFocus 2022
The Apis Team will be attending and exhibiting in person at Bionow’s BioFocus 2022 in Newcastle, UK.
This event showcases the incredible successes and development of the life science and healthcare sectors in the NE of England.
Interested in learning more? Use this link to contact us and schedule a meeting.